Evidence map›Paper›PMID 39654285›Full record

ArticleClinical cardiology2024

Physician and Patient Preferences for Oral Anticoagulation Therapy Decision Making in Atrial Fibrillation: Results From a National Best-Worst Scaling Survey in Türkiye.

K Kılıckesmez, D Aras, M Degertekin, N Ozer, B Hacibedel, K Helvacioglu, U Koc, B Ozdengulsun, E Dundar Ahi, O Ergene

Erratum issuedAbstract read
In one paragraph

Article in Clinical cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

K KılıckesmezDepartment of Cardiology, Cemil Taşcıoğlu Research and Training Hospital, İstanbul, Türkiye.
D ArasDepartment of Cardiology, Medipol University, İstanbul, Türkiye.
M DegertekinDepartment of Cardiology, Yeditepe University, İstanbul, Türkiye.
N OzerDepartment of Cardiology, Hacettepe University, Ankara, Türkiye.
B HacibedelPfizer, İstanbul, Türkiye.
K HelvaciogluPfizer, İstanbul, Türkiye.
U KocPfizer, İstanbul, Türkiye.
B OzdengulsunPfizer, İstanbul, Türkiye.
E Dundar AhiPfizer, İstanbul, Türkiye.
O ErgeneDepartment of Cardiology, Dokuz Eylül University, İzmir, Türkiye.

Funding

This research was sponsored by Pfizer.
6 · The paper itself

Abstract

Atrial fibrillation (AF) is the most common cardiac dysrhythmia and a common cause of ischemic stroke. Stroke prevention with oral anticoagulation (OAC) is the cornerstone of AF management. Patients and their treating physicians may have different views on different attributes of OACs. The objective of this study was to quantify the relative importance that patients and physicians in Turkey place on different OAC attributes when making treatment decisions in AF. A cross-sectional survey was administered to AF patients (≥ 50 years) receiving OAC and practising cardiologists, including residents with ≥ 2 years of experience in Turkey. For both patients (N = 230; 50% male) and physicians (N = 194; 74% male), the most important attributes for OAC treatment decision making in AF were "success in preventing stroke" (57% and 73.9% or overall importance, respectively) and "risk of major bleeding" (20% and 23.4%, respectively). For patients, other attributes were much less important, but not altogether unimportant: reversal agent availability (7%), monitoring (5%), food or drug interactions (3%), minor bleeding (3%), and ease of swallowing (2%). For physicians, among the other attributes, only the need for monitoring (1.3%) had a relative importance of > 1%. For all Turkish participants, efficacy and safety were found to be the most important attributes influencing OAC choice in AF with these two attributes accounting for 77% and 97.3% of overall importance for patients and physicians, respectively. Certain considerations, especially reversal agent availability and monitoring appear to be more important to patients than to physicians This is the first study to use BWS to quantify patient and physician preferences for OAC treatments in AF in Turkey.

Indexed as

AnticoagulantsAtrial FibrillationPatient PreferenceAdministration, OralAgedClinical Decision-MakingCross-Sectional StudiesFemaleHealth Care SurveysHemorrhageHumansMaleMiddle AgedPractice Patterns, Physicians'Risk FactorsStrokeAnticoagulantsatrial fibrilationNOACsoral anticoagulationpatients' preferencestreatment decision

Identifiers

PMID39654285
PMCPMC11628632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.